Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers

Novo Nordisk announced it will offer its diabetes drug Ozempic for $499 per month to eligible cash-paying U.S. customers through its own pharmacy and partners like GoodRx, a strategy mirroring its existing Wegovy sales. This direct-to-consumer push, aimed at uninsured patients and designed to counter cheaper compounded versions and rival Eli Lilly's direct offerings, sent Novo Nordisk shares up 5.3% and GoodRx shares soaring 34.2%. The company anticipates these cash sales will eventually account for approximately 10% of total Ozempic prescriptions, enhancing market access and competitive positioning.

Analysis

Novo Nordisk is strategically expanding its direct-to-consumer (DTC) model by offering its diabetes drug Ozempic at $499 per month to eligible cash-paying U.S. patients. This move, facilitated through its proprietary pharmacy and partnerships with telehealth services like GoodRx, directly mirrors the company's existing successful strategy for its weight-loss drug, Wegovy. The initiative is a direct response to dual competitive pressures: the proliferation of cheaper, compounded versions of the drug and aggressive pricing from rival Eli Lilly, which offers its weight-loss drug Zepbound directly for a similar price. The market reacted with significant optimism, sending Novo Nordisk's U.S. shares up 5.3% and partner GoodRx's shares soaring 34.2%. Novo management has set a clear performance benchmark, anticipating that cash sales from this channel will eventually account for approximately 10% of total Ozempic prescriptions, matching the penetration level seen with Wegovy. This strategic pivot is further bolstered by recent positive regulatory news, including the FDA's approval for Wegovy to treat the liver disease MASH, which also contributed to the upward stock movement.

Key Decisions for Investors

• Investors should view Novo Nordisk's direct-to-consumer strategy for Ozempic as a key initiative to capture the uninsured market, defend market share, and potentially add a new revenue stream if the projected 10% penetration target is met.
• The 34.2% surge in GoodRx's stock underscores the material impact of this partnership, and its future performance will be closely tied to the execution and sales volume generated through this new channel.
• Holders of Eli Lilly should monitor for a competitive response, as Novo's move into the direct-to-consumer diabetes market with Ozempic creates a new pressure point where Lilly's comparable drug, Mounjaro, is not yet directly offered.